Conclusion
In conclusion, we provide a case of pembrolizumab-induced cardiomyopathy, a rare treatment-associated side effect with no proven cure. Reintroducing ICI treatment after efficient management of myocarditis is under study worldwide as it is one of the most promising medications for improving survival in patients with NSCLC and other solid tumors. However, more research is needed to find the best patient features for reintroducing ICI treatment safely while reducing the risk of recurrent myocarditis.